Loading market dashboard
Liquidia Corporation
LQDAHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Fragile Iran ceasefire keeps stocks volatile. Low-beta picks LQDA, CVX, OXY and VLO show recent gains and solid volume.
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.
Does Liquidia Corporation (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.
MORRISVILLE, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company's business in a fireside chat at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 12:45 p.m.
Middle East tensions are stoking volatility; a low-beta screen spotlights Liquidia, Exxon Mobil, Valero Energy and Diamondback Energy.
Liquidia Corporation (LQDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Liquidia Corporation (LQDA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Liquidia develops therapies for rare cardiopulmonary diseases, leveraging proprietary drug delivery technologies in the U.S. market.
LQDA, NEXA and NUE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 13th, 2026.
HCSG, NUE, NEXA, LQDA and NKSH have been added to the Zacks Rank #1 (Strong Buy) List on May 13th, 2026.
Liquidia Corp (NASDAQ:LQDA) on Monday reported better-than-expected first-quarter financial results.
Liquidia delivered strong Q1 results, with Yutrepia net sales up 44% sequentially and a third consecutive profitable quarter. LQDA now commands a 23% share of the inhaled prostacyclin segment, but further market share gains are likely capped by entrenched competitors and limited product differentiation. At a near $5 billion market cap and 9x run-rate revenue, the current valuation assumes sustained momentum and peak Yutrepia sales north of $1.2 billion, which appears optimistic.
Liquidia Corporation (LQDA) Q1 2026 Earnings Call Transcript
Liquidia NASDAQ: LQDA reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Liquidia Corporation (LQDA) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to a loss of $0.45 per share a year ago.
YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between launch in June 2025 and April 30, 2026 Recorded third consecutive quarter of profitability, with net income of approximately $53 million, adjusted EBITDA of $71 million and an increase in cash and cash equivalents by $32 million compared to the fourth quarter of 2025 Actively screening PH-ILD patients in Phase 4 Tyvaso® and Tyvaso DPI® transition study and pivotal Phase 3 Re-Spire study of L606 MORRISVILLE, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the first quarter ended March 31, 2026.
Low beta screen highlights LQDA, CBOE, VLO and FANG as Middle East tensions keep U.S. stocks volatile, and investors favor steadier movers.
MORRISVILLE, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced it will participate in upcoming investor conferences.
INTT, EOG, UVE, LQDA and UMBF have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2026.
MORRISVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its first quarter 2026 financial results on Monday, May 11, 2026.
This drug stock is testing a moving average in a base. This biopharma name has a patented technology to administer its drug.
53,300 shares were sold indirectly for a transaction value of ~$2.14 million across April 14, 2026, to April 16, 2026, at a weighted average price of around $40.21 per share. Direct and indirect holdings are now at 1,137,599 and 1,441,934 shares, respectively.
Liquidia Corporation (NASDAQ: LQDA - Get Free Report) CEO Roger Jeffs sold 25,000 shares of Liquidia stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $40.14, for a total value of $1,003,500.00. Following the completion of the transaction, the chief executive officer directly owned 1,466,934 shares of the
Liquidia Corporation (NASDAQ: LQDA - Get Free Report) CFO Michael Kaseta sold 139,390 shares of the company's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $40.14, for a total transaction of $5,595,114.60. Following the completion of the sale, the chief financial officer owned 353,356 shares of the
Liquidia Corporation (NASDAQ: LQDA - Get Free Report)'s stock price dropped 7.9% during mid-day trading on Friday after an insider sold shares in the company. The stock traded as low as $37.90 and last traded at $38.1370. Approximately 1,126,102 shares were traded during trading, a decline of 35% from the average daily volume of 1,745,329 shares.
Liquidia Corporation (NASDAQ: LQDA - Get Free Report) CEO Roger Jeffs sold 32,744 shares of Liquidia stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $38.37, for a total transaction of $1,256,387.28. Following the completion of the transaction, the chief executive officer directly owned 1,137,599 shares of the
Liquidia Corporation (NASDAQ: LQDA - Get Free Report) CFO Michael Kaseta sold 133,789 shares of the business's stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $40.24, for a total transaction of $5,383,669.36. Following the completion of the sale, the chief financial officer directly owned 411,855 shares in
SG Americas Securities LLC lifted its holdings in shares of Liquidia Corporation (NASDAQ: LQDA) by 46.7% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 54,696 shares of the company's stock after purchasing an additional 17,407 shares during the period. SG Americas Securities
Shares of Liquidia Corporation (NASDAQ: LQDA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twelve brokerages that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, seven have given a buy recommendation and two
Director Stephen Bloch sold 70,234 shares indirectly through Canaan VIII, L.P. in open-market transactions on March 26 and March 27, 2026.
The mean of analysts' price targets for Liquidia Corporation (LQDA) points to a 34.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Liquidia Corporation (NASDAQ: LQDA - Get Free Report) Director Stephen Bloch sold 62,550 shares of the stock in a transaction that occurred on Friday, March 27th. The stock was sold at an average price of $35.94, for a total transaction of $2,248,047.00. Following the completion of the transaction, the director owned 2,188,935 shares in the company,
Scott Moomaw sold 80,000 shares of common stock for a transaction value of approximately ~$2.83 million on March 9, 2026. The transaction represented 29.74% of his direct holdings, reducing direct ownership to 188,954 shares after the sale.
Liquidia Corporation (NASDAQ: LQDA - Get Free Report) insider Scott Moomaw sold 18,314 shares of the firm's stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $36.79, for a total transaction of $673,772.06. Following the sale, the insider owned 187,640 shares in the company, valued at approximately $6,903,275.60.
The chief medical officer of Liquidia sold 35,365 common shares on March 13, 2026, for a transaction value of $1.28 million at around $36.30 per share. The sale was executed entirely from direct holdings; no indirect or derivative securities were involved.
Low-beta picks gain focus as Iran war fears stir volatility. AGRO, PRA, E and LQDA reflect resilience with momentum, liquidity and fundamentals.
Liquidia Corporation (LQDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The average of price targets set by Wall Street analysts indicates a potential upside of 35.4% in Liquidia Corporation (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Apis Capital Advisors LLC bought a new position in shares of Liquidia Corporation (NASDAQ: LQDA) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 420,800 shares of the company's stock, valued at approximately $9,569,000. Liquidia accounts for about 2.1% of Apis Capital Advisors
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA in this volatile sector.
STRL, LQDA and NWPX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 10th, 2026.
Liquidia (NASDAQ: LQDA) executives highlighted a rapid commercial ramp for YUTREPIA, expanding clinical plans for both YUTREPIA and the next-generation candidate L-606, and improving profitability during the company's full year 2025 financial results and corporate update call. Commercial launch metrics and prescribing trends Chief Executive Officer Dr. Roger Jeffs said 2025 demonstrated Liquidia's ability to "launch,
